Palvella Therapeutics
PVLA
97 hedge funds and large institutions have $129M invested in Palvella Therapeutics in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 29 reducing their positions, and 24 closing their positions.
33% more capital invested
Capital invested by funds: $96.9M → $129M (+$31.7M)
0.09% more ownership
Funds ownership: 0.72% → 0.81% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
7% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 29
1% less funds holding
Funds holding: 98 → 97 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.79M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$6.96M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.65M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.87M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.45M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.08M |
| 3 |
Renaissance Technologies
New York
|
-$711K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$703K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$513K |
PVLA Hedge Fund Activity: Q4 2019 in Review
97 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2019, worth a combined $129M — up 33% from $96.9M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PVLA and 23 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 27 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $8.79M. The largest seller was Acadian Asset Management, cutting an estimated $4.45M.
- 97 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2019, down from 98 in Q3 2019.
- Funds reported $129M of Palvella Therapeutics stock for Q4 2019, up 33% quarter-over-quarter.
- 23 funds opened new Palvella Therapeutics positions in Q4 2019 and 24 closed out, a net change of -1 holder.
- The largest Palvella Therapeutics buyer in Q4 2019 was EcoR1 Capital, an estimated $8.79M added.
- The largest Palvella Therapeutics seller in Q4 2019 was Acadian Asset Management, an estimated $4.45M sold.
Based on aggregated 13F filings for Q4 2019.